2 Firms Steer Singaporean Biotech Firm's $400M SPAC Merger
Singapore-based oncology firm AUM Biosciences Pte. Ltd. and Mountain Crest Acquisition Corp. V on Thursday said they have agreed to a merger that would take AUM public at an estimated $400...To view the full article, register now.
Already a subscriber? Click here to view full article